ClinicalTrials.gg
CompletedNCT01412957Updated Mar 15, 2017Results posted

Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

A Phase 3 interventional study of Best Supportive Care (BSC) and Panitumumab in Metastatic Colorectal Cancer, sponsored by Amgen. Completed at 78 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-15.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
377
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
15th of 88
377 · median 70
Started
2011
with 4 others
Phase 3
14 of 90
2 open now
Registered
47th of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 15th largest by enrollment of the 88 interventional ones that give a count, is one of 5 that started in 2011, is one of 14 in phase 3, and was the 47th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the benefit of panitumumab in addition to best supportive care compared to best supportive care alone in patients with chemorefractory wild-type KRAS (Kirsten rat sarcoma viral oncogene homolog) metastatic colorectal cancer.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Best Supportive Care
  • Panitumumab
  • Chemorefractory
  • Wild-type KRAS
  • Overall Survival
  • Phase 3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of colorectal cancer (CRC)
  • Wild-type (without mutation in codons 12 and 13) KRAS gene in tumor tissue confirmed by a central laboratory
  • (ECOG) performance status of 0, 1 or 2
  • At least 1 measurable or non- per (RECIST) version 1.1 guidelines.
  • Treatment failure (defined as failure due to either disease progression [clinical or radiological] or toxicity [treatment intolerance]) of a prior regimen containing irinotecan for metastatic disease and a prior regimen containing oxaliplatin for metastatic disease. Oxaliplatin and irinotecan may have been administered sequentially or in combination.

    • Disease relapse within 6 months after completing chemotherapy (with either an irinotecan or oxaliplatin containing regimen) will also be considered as treatment failure of a prior regimen for metastatic disease
  • Must have previously received a thymidylate synthase inhibitor (eg, fluorouracil, capecitabine, raltitrexed, or fluorouracil-uracil) at any point for treatment of CRC
  • Man or woman at least 18 years of age
  • Adequate hematologic, renal, hepatic and metabolic function
  • Negative pregnancy test within 72 hours before randomization (for women of only)
  • Subject or subject's legally acceptable representative has provided .
  • Other protocol-specified criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Symptomatic requiring treatment
  • History of another primary cancer within 5 years of randomization
  • Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (eg, panitumumab or cetuximab) or treatment with small molecule EGFR inhibitors (eg, gefitinib, erlotinib, lapatinib)
  • Antitumor therapy (eg, chemotherapy, hormonal therapy, immunotherapy, antibody therapy) within 21 days before randomization
  • Radiotherapy within 14 days before randomization.
  • Exclusion Criteria for (QTc) Evaluation Subpart of the Study: Prolongation of QT/QTc interval > 450 milliseconds at screening
  • Other protocol-specified criteria may apply
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
377 participants (actual)

Study arms

  • Experimental
    Panitumumab + BSC

    Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus BSC until disease progression, withdrawal of consent, death, or intolerance of study drug.

    Other: Best Supportive Care (BSC) · Drug: Panitumumab

  • Other
    BSC Alone

    Participants received best supportive care until disease progression, withdrawal of consent, or death.

    Other: Best Supportive Care (BSC)

Interventions

  • OtherBest Supportive Care (BSC)

    BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated.

  • Administered intravenously

    Also known as: Vectibix

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival was defined as the time from the randomization date to the date of death. Participants who had not died by the analysis data cut-off date were censored at their last contact date and participants with survival data obtained after the planned analysis data cut-off date had survival censored at the cut-off date.

    Time frame: From randomization to the last on-study or long-term follow-up visit, as of the data cut-off date of 10 June 2014. The median follow-up time was 34.9 weeks (panitumumab plus BSC: 41.0 weeks; BSC alone: 25.5 weeks).

Secondary outcomes

  1. Progression-free Survival

    Progression-free survival (PFS) was defined as the time from the randomization date to the date of disease progression per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death. Progressive disease (PD): At least a 20% increase in the size of target lesions compared with the smallest size since treatment started and an absolute increase of at least 5 mm, any new lesions or an increase in size of non-target lesions thought be ≥ 20% and an absolute increase of at least 5 mm, or significant increase in pleural effusions, ascites or other fluid collections with cytologic proof of malignancy. Participants who were alive and did not meet the criteria for progression by the analysis data cut-off date were censored at their last evaluable disease assessment date.

    Time frame: From randomization to the last on-study or long-term follow-up visit, as of the data cut-off date of 10 June 2014. The median follow-up time was 34.9 weeks (panitumumab plus BSC: 41.0 weeks; BSC alone: 25.5 weeks).

  2. Overall Survival in Participants With Wild-type RAS

    A secondary efficacy endpoint was overall survival in participants with wild-type rat sarcoma viral oncogene homolog (RAS) (without mutation in exons 2 \[codons 12 and 13\], 3 \[codons 59 and 61\], and 4 \[codons 117 and 146\] of KRAS and neuroblastoma RAS viral oncogene (NRAS)). In participants with wild-type RAS, RAS mutation status was defined by KRAS exon 2 mutation status per clinical trial assay testing and mutation status of KRAS exon 3 and 4 and NRAS exons 2, 3 and 4 per Sanger bi-directional sequencing. Overall survival was defined as the time from the randomization date to the date of death. Participants who had not died by the analysis data cut-off date were censored at their last contact date and participants with survival data obtained after the planned analysis data cut-off date had survival censored at the cut-off date.

    Time frame: From randomization to the last on-study or long-term follow-up visit, as of the data cut-off date of 10 June 2014. The median follow-up time was 36.1 weeks (panitumumab plus BSC: 43.7 weeks; BSC alone: 23.6 weeks).

  3. Progression Free Survival (PFS) in Participants With Wild-type RAS

    PFS was defined as the time from the randomization date to the date of disease progression per RECIST version 1.1 or death. Progressive disease (PD): At least a 20% increase in the size of target lesions compared with the smallest size since treatment started and an absolute increase of at least 5 mm, any new lesions, or an increase in size of non-target lesions thought be ≥ 20% with an absolute increase of at least 5 mm, or significant increase in pleural effusions, ascites or other fluid collections with cytologic proof of malignancy. Participants who were alive and did not meet the criteria for progression by the analysis data cut-off date were censored at their last evaluable disease assessment date.

    Time frame: From randomization to the last on-study or long-term follow-up visit, as of the data cut-off date of 10 June 2014. The median follow-up time was 36.1 weeks (panitumumab plus BSC: 43.7 weeks; BSC alone: 23.6 weeks).

  4. Objective Response Rate

    Objective response rate (ORR) is defined as the percentage of participants with either a complete response (CR) or partial response (PR) per RECIST version 1.1. Radiographic tumor assessments and investigator's assessment of response were performed at Week 4, Week 8, and then every 8 weeks until disease progression (radiographic or clinical progression). CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions with persistence of one or more non-target lesions not qualifying for either CR or PD and no new lesions.

    Time frame: Response was assessed at Week 4, Week 8, and then every 8 weeks until the data cut-off date of 10 June 2014. The median follow-up time was 34.9 weeks (panitumumab plus BSC: 41.0 weeks; BSC alone: 25.5 weeks).

  5. Objective Response Rate in Participants With Wild-type RAS

    Objective response rate is defined as the percentage of participants with either a complete response (CR) or partial response (PR) per RECIST version 1.1. Radiographic tumor assessments and investigator's assessment of response were performed at Week 4, Week 8, and then every 8 weeks until disease progression (radiographic or clinical progression). CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions with persistence of one or more non-target lesions not qualifying for either CR or PD and no new lesions.

    Time frame: Response was assessed at Week 4, Week 8, and then every 8 weeks until the data cut-off date of 10 June 2014. The median follow-up time was 36.1 weeks (panitumumab plus BSC: 43.7 weeks; BSC alone: 23.6 weeks).

  6. Number of Participants With Adverse Events (AEs)

    The severity of each AE was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (Grade 1 = Mild; 2 = Moderate (discomfort enough to cause interference with usual activity); 3 = Severe (incapacitating with inability to work or do usual activity); 4 = Life-threatening and 5 = Fatal), with the exception of the skin-or nail-related AEs which were graded using a CTCAE version 3.0 with modifications. A serious AE was defined as an AE that met at least 1 of the following criteria: • fatal, • life-threatening, • required in-patient hospitalization or prolongation of existing hospitalization, • resulted in persistent or significant disability/incapacity, • congenital anomaly/birth defect, and/or • other medically important serious event. Treatment-related AEs (TRAEs) are those the investigator considered there was reasonable possibility that the event might have been caused by study drug.

    Time frame: From first dose until 30 days after last dose; median safety reporting periods were 4.2 months and 2.2 months for panitumumab plus BSC arm and BSC alone arm, respectively.

  7. Maximum Post-baseline Change From Baseline in Corrected QT (QTc) Interval

    QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by electrocardiogram (ECG). QTc is the QT interval corrected for heart rate. To evaluate the effect of panitumumab treatment on the QTc interval length among participants treated with panitumumab, ECGs were collected at the following time points from participants randomized to panitumumab arm at a limited number of sites: Week 1 prior to the first panitumumab infusion (Baseline) and within 30 minutes following the end of the first infusion of panitumumab (Cmax), Week 7 after 3 doses of panitumumab (steady state), and at the safety follow-up visit. The ECGs were submitted for independent central review to calculate the reported QTc interval. QTc was calculated using both the Bazett correction (QTcB) and the Fridericia correction (QTcF).

    Time frame: Baseline (pre-dose), Week 1 and Week 7 (post-dose) and 4 weeks after the last dose (Safety Follow-up visit)

07

Results

Posted Apr 8, 2016

Participant flow

A total of 377 participants were randomized at 66 centers in Europe, Asia, North and South America from 8 November 2011 until 30 July 2013. Results are reported as of the primary analysis data cut-off date of 10 June 2014.

Participant flow — Overall Study
MilestonePanitumumab + BSCBSC Alone
Started189188
Completed4031
Not completed149157
Withdrew: Withdrawal by subject622
Withdrew: Lost to follow-up72
Withdrew: Death136133

Outcome measures

PrimaryOverall Survival

Overall survival was defined as the time from the randomization date to the date of death. Participants who had not died by the analysis data cut-off date were censored at their last contact date and participants with survival data obtained after the planned analysis data cut-off date had survival censored at the cut-off date.

Time frame:
From randomization to the last on-study or long-term follow-up visit, as of the data cut-off date of 10 June 2014. The median follow-up time was 34.9 weeks (panitumumab plus BSC: 41.0 weeks; BSC alone: 25.5 weeks).
Reported as:
Median · months
Overall Survival
monthsPanitumumab + BSCBSC Alone
Overall Survival10.0 (8.7 to 11.4)7.4 (5.8 to 9.3)
Statistical analysis
  • Panitumumab + BSC vs BSC Alone · Log Rank · p = 0.0096 · Normal score: -2.59A normal score \< 0 indicates fewer than expected events for the panitumumab plus BSC arm and therefore a longer time to event.
SecondaryProgression-free Survival

Progression-free survival (PFS) was defined as the time from the randomization date to the date of disease progression per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death. Progressive disease (PD): At least a 20% increase in the size of target lesions compared with the smallest size since treatment started and an absolute increase of at least 5 mm, any new lesions or an increase in size of non-target lesions thought be ≥ 20% and an absolute increase of at least 5 mm, or significant increase in pleural effusions, ascites or other fluid collections with cytologic proof of malignancy. Participants who were alive and did not meet the criteria for progression by the analysis data cut-off date were censored at their last evaluable disease assessment date.

Time frame:
From randomization to the last on-study or long-term follow-up visit, as of the data cut-off date of 10 June 2014. The median follow-up time was 34.9 weeks (panitumumab plus BSC: 41.0 weeks; BSC alone: 25.5 weeks).
Reported as:
Median · months
Progression-free Survival
monthsPanitumumab + BSCBSC Alone
Progression-free Survival3.6 (3.4 to 5.3)1.7 (1.6 to 1.9)
Statistical analysis
  • Panitumumab + BSC vs BSC Alone · Log Rank · p = <0.0001 · Normal score: -6.08A normal score \< 0 indicates fewer than expected events for the panitumumab plus BSC arm and therefore a longer time to event.
SecondaryOverall Survival in Participants With Wild-type RAS

A secondary efficacy endpoint was overall survival in participants with wild-type rat sarcoma viral oncogene homolog (RAS) (without mutation in exons 2 \[codons 12 and 13\], 3 \[codons 59 and 61\], and 4 \[codons 117 and 146\] of KRAS and neuroblastoma RAS viral oncogene (NRAS)). In participants with wild-type RAS, RAS mutation status was defined by KRAS exon 2 mutation status per clinical trial assay testing and mutation status of KRAS exon 3 and 4 and NRAS exons 2, 3 and 4 per Sanger bi-directional sequencing. Overall survival was defined as the time from the randomization date to the date of death. Participants who had not died by the analysis data cut-off date were censored at their last contact date and participants with survival data obtained after the planned analysis data cut-off date had survival censored at the cut-off date.

Time frame:
From randomization to the last on-study or long-term follow-up visit, as of the data cut-off date of 10 June 2014. The median follow-up time was 36.1 weeks (panitumumab plus BSC: 43.7 weeks; BSC alone: 23.6 weeks).
Reported as:
Median · months
Overall Survival in Participants With Wild-type RAS
monthsPanitumumab + BSCBSC Alone
Overall Survival in Participants With Wild-type RAS10.0 (8.7 to 11.6)6.9 (5.2 to 7.9)
Statistical analysis
  • Panitumumab + BSC vs BSC Alone · Log Rank · p = 0.0135 · Normal score: -2.47A normal score \< 0 indicates fewer than expected events for the panitumumab plus BSC arm and therefore a longer time to event.
SecondaryProgression Free Survival (PFS) in Participants With Wild-type RAS

PFS was defined as the time from the randomization date to the date of disease progression per RECIST version 1.1 or death. Progressive disease (PD): At least a 20% increase in the size of target lesions compared with the smallest size since treatment started and an absolute increase of at least 5 mm, any new lesions, or an increase in size of non-target lesions thought be ≥ 20% with an absolute increase of at least 5 mm, or significant increase in pleural effusions, ascites or other fluid collections with cytologic proof of malignancy. Participants who were alive and did not meet the criteria for progression by the analysis data cut-off date were censored at their last evaluable disease assessment date.

Time frame:
From randomization to the last on-study or long-term follow-up visit, as of the data cut-off date of 10 June 2014. The median follow-up time was 36.1 weeks (panitumumab plus BSC: 43.7 weeks; BSC alone: 23.6 weeks).
Reported as:
Median · months
Progression Free Survival (PFS) in Participants With Wild-type RAS
monthsPanitumumab + BSCBSC Alone
Progression Free Survival (PFS) in Participants With Wild-type RAS5.2 (3.5 to 5.3)1.7 (1.6 to 2.2)
Statistical analysis
  • Panitumumab + BSC vs BSC Alone · Log Rank · p = <0.0001 · Normal score: -5.98A normal score \< 0 indicates fewer than expected events for the panitumumab plus BSC arm and therefore a longer time to event.
SecondaryObjective Response Rate

Objective response rate (ORR) is defined as the percentage of participants with either a complete response (CR) or partial response (PR) per RECIST version 1.1. Radiographic tumor assessments and investigator's assessment of response were performed at Week 4, Week 8, and then every 8 weeks until disease progression (radiographic or clinical progression). CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions with persistence of one or more non-target lesions not qualifying for either CR or PD and no new lesions.

Time frame:
Response was assessed at Week 4, Week 8, and then every 8 weeks until the data cut-off date of 10 June 2014. The median follow-up time was 34.9 weeks (panitumumab plus BSC: 41.0 weeks; BSC alone: 25.5 weeks).
Reported as:
Number · percentage of participants
Objective Response Rate
percentage of participantsPanitumumab + BSCBSC Alone
Objective Response Rate26.98 (20.80 to 33.91)1.60 (0.33 to 4.59)
Statistical analysis
  • Panitumumab + BSC vs BSC Alone · Stratified exact test · p = <0.0001 · Odds ratio (or): 24.89 · 95% CI 7.47 to 123.77The odds ratio is defined as the odds of having an objective response in the panitumumab plus BSC arm relative to the odds in BSC alone arm.
SecondaryObjective Response Rate in Participants With Wild-type RAS

Objective response rate is defined as the percentage of participants with either a complete response (CR) or partial response (PR) per RECIST version 1.1. Radiographic tumor assessments and investigator's assessment of response were performed at Week 4, Week 8, and then every 8 weeks until disease progression (radiographic or clinical progression). CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions with persistence of one or more non-target lesions not qualifying for either CR or PD and no new lesions.

Time frame:
Response was assessed at Week 4, Week 8, and then every 8 weeks until the data cut-off date of 10 June 2014. The median follow-up time was 36.1 weeks (panitumumab plus BSC: 43.7 weeks; BSC alone: 23.6 weeks).
Reported as:
Number · percentage of participants
Objective Response Rate in Participants With Wild-type RAS
percentage of participantsPanitumumab + BSCBSC Alone
Objective Response Rate in Participants With Wild-type RAS30.99 (23.50 to 39.28)2.34 (0.49 to 6.70)
Statistical analysis
  • Panitumumab + BSC vs BSC Alone · Stratified exact test · p = <0.0001 · Odds ratio (or): 20.00 · 95% CI 5.89 to 101.62The odds ratio is defined as the odds of having an objective response in the panitumumab plus BSC arm relative to the odds in BSC alone arm.
SecondaryNumber of Participants With Adverse Events (AEs)

The severity of each AE was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (Grade 1 = Mild; 2 = Moderate (discomfort enough to cause interference with usual activity); 3 = Severe (incapacitating with inability to work or do usual activity); 4 = Life-threatening and 5 = Fatal), with the exception of the skin-or nail-related AEs which were graded using a CTCAE version 3.0 with modifications. A serious AE was defined as an AE that met at least 1 of the following criteria: • fatal, • life-threatening, • required in-patient hospitalization or prolongation of existing hospitalization, • resulted in persistent or significant disability/incapacity, • congenital anomaly/birth defect, and/or • other medically important serious event. Treatment-related AEs (TRAEs) are those the investigator considered there was reasonable possibility that the event might have been caused by study drug.

Time frame:
From first dose until 30 days after last dose; median safety reporting periods were 4.2 months and 2.2 months for panitumumab plus BSC arm and BSC alone arm, respectively.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsPanitumumab + BSCBSC Alone
Any adverse event (AE)184115
AE with worst grade of 37029
AE with worst grade of 4175
AE with worst grade of 5815
Serious adverse event (SAE)4837
AE leading to discontinuation of panitumumab20NA
Treatment-related adverse event (TRAE)1667
Treatment-related AE with worst grade of 3411
Treatment-related AE with worst grade of 441
Treatment-related AE with worst grade of 501
Serious treatment-related AE23
TRAE leading to discontinuation of panitumumab1NA
SecondaryMaximum Post-baseline Change From Baseline in Corrected QT (QTc) Interval

QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by electrocardiogram (ECG). QTc is the QT interval corrected for heart rate. To evaluate the effect of panitumumab treatment on the QTc interval length among participants treated with panitumumab, ECGs were collected at the following time points from participants randomized to panitumumab arm at a limited number of sites: Week 1 prior to the first panitumumab infusion (Baseline) and within 30 minutes following the end of the first infusion of panitumumab (Cmax), Week 7 after 3 doses of panitumumab (steady state), and at the safety follow-up visit. The ECGs were submitted for independent central review to calculate the reported QTc interval. QTc was calculated using both the Bazett correction (QTcB) and the Fridericia correction (QTcF).

Time frame:
Baseline (pre-dose), Week 1 and Week 7 (post-dose) and 4 weeks after the last dose (Safety Follow-up visit)
Reported as:
Mean · msec
Maximum Post-baseline Change From Baseline in Corrected QT (QTc) Interval
msecPanitumumab + BSCBSC Alone
QTcF14.58 ± 13.60—
QTcB12.57 ± 12.15—

Adverse events

Collected over From first dose until 30 days after last dose; median safety reporting periods were 4.2 months and 2.2 months for panitumumab plus BSC arm and BSC alone arm, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab Plus BSC—48/189 (25.4%)174/189 (92.1%)
BSC Alone—37/188 (19.7%)74/188 (39.4%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventPanitumumab Plus BSCBSC Alone
Abdominal painGastrointestinal disorders3/1893/188
Intestinal obstructionGastrointestinal disorders3/1893/188
General physical health deteriorationGeneral disorders0/1893/188
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1893/188
Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1893/188
IleusGastrointestinal disorders3/1891/188
AnaemiaBlood and lymphatic system disorders1/1892/188
FatigueGeneral disorders1/1892/188
PyrexiaGeneral disorders0/1892/188
HeadacheNervous system disorders0/1892/188
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPanitumumab Plus BSCBSC Alone
RashSkin and subcutaneous tissue disorders73/1892/188
Dermatitis acneiformSkin and subcutaneous tissue disorders54/1890/188
HypomagnesaemiaMetabolism and nutrition disorders53/1892/188
PruritusSkin and subcutaneous tissue disorders47/1890/188
Dry skinSkin and subcutaneous tissue disorders29/1891/188
Abdominal painGastrointestinal disorders28/18918/188
FatigueGeneral disorders28/18914/188
ParonychiaInfections and infestations27/1890/188
AcneSkin and subcutaneous tissue disorders26/1890/188
DiarrhoeaGastrointestinal disorders25/1897/188

Baseline characteristics

Age, Continuous
Age, Continuous(years)Panitumumab + BSCBSC AloneTotal
Mean60.2 ± 10.758.7 ± 11.159.4 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab + BSCBSC AloneTotal
Female8279161
Male107109216
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Panitumumab + BSCBSC AloneTotal
Hispanic or Latino232245
Not Hispanic or Latino166166332
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Panitumumab + BSCBSC AloneTotal
American Indian or Alaska Native033
Asian7982161
White107102209
Other314
Geographic Region
Geographic Region(participants)Panitumumab + BSCBSC AloneTotal
Europe8685171
Asia8082162
Rest of world232144
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Panitumumab + BSCBSC AloneTotal
Grade 07165136
Grade 1100107207
Grade 2181634
Location of Primary Tumor
Location of Primary Tumor(participants)Panitumumab + BSCBSC AloneTotal
Colon108106214
Rectum8181162
Missing011
08

Study locations

78 sites
  • Research Site
    Curitiba, Paraná 80420-090, Brazil
  • Research Site
    Natal, Rio Grande do Norte 59075-740, Brazil
  • Research Site
    Ijui, Rio Grande do Sul 98700-000, Brazil
  • Research Site
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Research Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
  • Research Site
    Montreal, Quebec H4J 1C5, Canada
  • Research Site
    Québec, Quebec G1S 4L8, Canada
  • Research Site
    Trois-Rivières, Quebec G8Z 3R9, Canada
  • Research Site
    Quebec, G1R 2J6, Canada
  • Research Site
    Temuco, Cautín 4810469, Chile
  • Research Site
    Vina del Mar, Valparaíso 2520612, Chile
  • Research Site
    Fuzhou, Fujian 350001, China
  • Research Site
    Fuzhou, Fujian 350025, China
  • Research Site
    Shijiazhuang, Hebei 050011, China
  • Research Site
    Nanjing, Jiangsu 210029, China
  • Research Site
    Changchun, Jilin 130021, China
  • Research Site
    Shenyang, Liaoning 110001, China
  • Research Site
    Xi An, Shaanxi 710032, China
  • Research Site
    Xi An, Shaanxi 710061, China
  • Research Site
    Beijing, 100032, China
  • Research Site
    Chongqing, 400037, China
  • Research Site
    Chongqing, 400042, China
  • Research Site
    Shanghai, 200233, China
  • Research Site
    Osijek, 31000, Croatia
  • Research Site
    Pula, 52100, Croatia
  • Research Site
    Rijeka, 51000, Croatia
  • Research Site
    Split, 21000, Croatia
  • Research Site
    Zagreb, 10000, Croatia
  • Research Site
    Tallinn, 13419, Estonia
  • Research Site
    Tartu, 51014, Estonia
  • Research Site
    Athens, 11522, Greece
  • Research Site
    Chania, 73300, Greece
  • Research Site
    Hyderabad, Andhra Pradesh 500 024, India
  • Research Site
    Visakhapatnam, Andhra Pradesh 530 002, India
  • Research Site
    Bangalore, Karnataka 560 054, India
  • Research Site
    Kochi, Kerala 682 304, India
  • Research Site
    Mumbai, Maharashtra 400 012, India
  • Research Site
    Nashik, Maharashtra 422 004, India
  • Research Site
    Nashik, Maharashtra 422 005, India
  • Research Site
    Pune, Maharashtra 411 001, India
  • Research Site
    Chennai, Tamil Nadu 600 018, India
  • Research Site
    Goyang-si, Gyeonggi-do, 410-769, Korea, Republic of
  • Research Site
    Seoul, 120-752, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Seoul, 138-736, Korea, Republic of
  • Research Site
    Daugavpils, 5417, Latvia
  • Research Site
    Riga, 1002, Latvia
  • Research Site
    Riga, 1079, Latvia
  • Research Site
    Kaunas, 50009, Lithuania
  • Research Site
    Vilnius, 08660, Lithuania
  • Research Site
    Nilai, Negri Sembilan 71800, Malaysia
  • Research Site
    Georgetown, Pinang 10400, Malaysia
  • Research Site
    Kuala Lumpur, Wilayah Persekutuan 56000, Malaysia
  • Research Site
    Kuala Lumpur, Wilayah Persekutuan 59100, Malaysia
  • Research Site
    Mexico City, Distrito Federal 14080, Mexico
  • Research Site
    Mexico, Distrito Federal 06760, Mexico
  • Research Site
    Cuernavaca, Morelos 62290, Mexico
  • Research Site
    Oaxaca, 68000, Mexico
  • Research Site
    Davao City, Davao 8000, Philippines
  • Research Site
    Cebu City, 6000, Philippines
  • Research Site
    Manila, 1000, Philippines
  • Research Site
    Manila, 1008, Philippines
  • Research Site
    Pasay City, 1300, Philippines
  • Research Site
    Bucharest, 022328, Romania
  • Research Site
    Bucharest, 022338, Romania
  • Research Site
    Cluj-Napoca, 400006, Romania
  • Research Site
    Cluj-Napoca, 400015, Romania
  • Research Site
    Cluj-Napoca, 400058, Romania
  • Research Site
    Craiova, 200385, Romania
  • Research Site
    Craiova, 200642, Romania
  • Research Site
    Lasi, 700106, Romania
  • Research Site
    Ploiesti, 100337, Romania
  • Research Site
    Suceava, 720237, Romania
  • Research Site
    Timisoara, 300167, Romania
  • Research Site
    Belgrade, 11000, Serbia
  • Research Site
    Nis, 18000, Serbia
  • Research Site
    Sremska Kamenica, 21204, Serbia
09

References and documents

Publications

  • Kim TW, Elme A, Kusic Z, Park JO, Udrea AA, Kim SY, Ahn JB, Valencia RV, Krishnan S, Bilic A, Manojlovic N, Dong J, Guan X, Lofton-Day C, Jung AS, Vrdoljak E. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br J Cancer. 2016 Nov 8;115(10):1206-1214. doi: 10.1038/bjc.2016.309. Epub 2016 Oct 13. PubMed 27736842 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jun 2014 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 10 months after primary completion. A results delay was requested in Jul 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2011
First posted
Aug 9, 2011
Start
Nov 2011
Primary completionActual
Jun 2014
CompletionActual
Nov 2016
Results delay requested
Jul 21, 2015
Results first posted
Apr 8, 2016
Last update
Mar 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01412957
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 9, 2011
Start date
Nov 2011
Primary completion
Jun 2014
Completion
Nov 2016
Results posted
Apr 8, 2016
Last update
Mar 15, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion